LabPMM offers Clinical Services with Global Reach
The Laboratory for Personalized Molecular Medicine® (LabPMM®) at Invivoscribe offers internationally standardized flow and molecular testing of novel and proprietary biomarkers that are critically important for patient care.
LabPMM offers Clinical Services with Global Reach
The Laboratory for Personalized Molecular Medicine® (LabPMM®) at Invivoscribe offers internationally standardized flow and molecular testing of novel and proprietary biomarkers that are critically important for patient care.
Multiparametric Flow Cytometry Panels
Multiparametric Flow Cytometry Panels
LabPMM’s Multiparametric Flow Cytometry (MFC) Panels complement NGS testing –
streamlining clinical trials for accurate results comparisons.
LabPMM’s Multiparametric Flow Cytometry (MFC) Panels complement NGS testing – streamlining clinical trials for accurate results comparisons.
Companion Diagnostic (CDx) Services
Companion Diagnostic (CDx) Services
The fms related tyrosine kinase 3 (FLT3) is one of the most commonly mutated genes in acute myeloid leukemia (AML), occurring in approximately 30% of patients at the time of diagnosis1. Although generally associated with normal cytogenetics where patients have standard risk of relapse, FLT3 mutations have also been identified in sub-groups of patients with chromosomal abnormalities that are associated with high risk of disease relapse2-3.
The fms related tyrosine kinase 3 (FLT3) is one of the most commonly mutated genes in acute myeloid leukemia (AML), occurring in approximately 30% of patients at the time of diagnosis1. Although generally associated with normal cytogenetics where patients have standard risk of relapse, FLT3 mutations have also been identified in sub-groups of patients with chromosomal abnormalities that are associated with high risk of disease relapse2-3.
NGS Cancer Panels
NGS Cancer Panels
Cytogenetic identification of chromosome abnormalities has become essential for the clinical management of patients with leukemia and is currently used to help categorize patients into risk groups.
Cytogenetic identification of chromosome abnormalities has become essential for the clinical management of patients with leukemia and is currently used to help categorize patients into risk groups.
NGS MRD Services
MRD NGS Tests
LabPMM’s MRD services are NGS-based tests that can be used to detect clonal gene rearrangements identified at diagnosis within virtually all of the antigen receptor loci for both B- and T-cells.
LabPMM’s MRD services are NGS-based tests that can be used to detect clonal gene rearrangements identified at diagnosis within virtually all of the antigen receptor loci for both B- and T-cells.
Targeted Gene Services
Targeted Gene Services
Clonality NGS Services
Clonality NGS Services
The unique process of genetic rearrangements in the immunoglobulin (Ig) and T-cell receptor (TCR) gene loci during immune cell development and maturation generates a vast pool of genetically distinct cells.
The unique process of genetic rearrangements in the immunoglobulin (Ig) and T-cell receptor (TCR) gene loci during immune cell development and maturation generates a vast pool of genetically distinct cells.
Custom Assay Development Services
Custom Assay Development Services
In response to the FDA announcing its intention to dramatically expand its regulatory oversight of laboratory developed tests (LDTs), Invivoscribe is partnering with laboratories worldwide to help facilitate the conversion of LDTs into FDA-cleared assays, as we know the barriers to bringing new assays online are often the availability of resources and the cost of validation.
In response to the FDA announcing its intention to dramatically expand its regulatory oversight of laboratory developed tests (LDTs), Invivoscribe is partnering with laboratories worldwide to help facilitate the conversion of LDTs into FDA-cleared assays, as we know the barriers to bringing new assays online are often the availability of resources and the cost of validation.
